Volume 18, Number 5—May 2012
High Anti–Phenolic Glycolipid-I IgM Titers and Hidden Leprosy Cases, Amazon Region
Highlight and copy the desired format.
|EID||Salgado C, Ferreira D, Frade M, Guimarães L, Batista da Silva M, Barreto J, et al. High Anti–Phenolic Glycolipid-I IgM Titers and Hidden Leprosy Cases, Amazon Region. Emerg Infect Dis. 2012;18(5):889-890. https://dx.doi.org/10.3201/eid1805.111018|
|AMA||Salgado C, Ferreira D, Frade M, et al. High Anti–Phenolic Glycolipid-I IgM Titers and Hidden Leprosy Cases, Amazon Region. Emerging Infectious Diseases. 2012;18(5):889-890. doi:10.3201/eid1805.111018.|
|APA||Salgado, C., Ferreira, D., Frade, M., Guimarães, L., Batista da Silva, M., & Barreto, J. (2012). High Anti–Phenolic Glycolipid-I IgM Titers and Hidden Leprosy Cases, Amazon Region. Emerging Infectious Diseases, 18(5), 889-890. https://dx.doi.org/10.3201/eid1805.111018.|
To the Editor: Leprosy remains a serious public health issue. Although the World Health Organization elimination target was achieved in 2000, with a prevalence of <1 case/10,000 persons, despite progress since introduction of multidrug therapy (1), large pockets of poverty remain in which the disease is hyperendemic and underdiagnosed. In fact, in highly disease-endemic areas, the prevalence of previously undiagnosed leprosy cases in the general population has been reported to be 6× higher than the registered prevalence (2).
Most leprosy patients are in India and Brazil. In Brazil, new cases are concentrated in the Northeast, Midwest, and Amazon regions (from state capitals to the inner counties). Access to the health system is poor in these regions because of severe inequalities in the public health system of Brazil (3),
A total of 34,894 new cases were registered in Brazil during 2010 (4), corresponding to an incidence rate of 18.22 cases per 100,000 population. Pará State accounted for 10.2% of cases (3,562 cases), an incidence rate of 46.93 per 100,000 population. When only children <15 years of age were considered, Pará registered 389 new cases of leprosy in 2010, representing 10.9% of all cases, an incidence rate of 16.52 per 100,000 population. In Oriximiná, a county with 62,794 inhabitants in northwestern Pará, ≈800 km from Belém, Pará’s capital, a mean of 13.8 cases per year were registered for the past 5 years.
In 2010, in Oriximiná, we collected plasma samples from 138 students 8–18 years of age, from 35 leprosy patients who received a diagnosis during 2004–2009, and from 126 contacts of these patients (Federal University of Pará Research Ethics Committee protocol no. 197/07). We tested all of these samples for anti–phenolic glycolipid-I (PGL-I) IgM; 42% of students, 54.3% of case-patients, and 45% of case-patient contacts were seropositive. In addition to collecting samples, we clinically examined the leprosy patients and their contacts, among whom we identified 3 new leprosy cases. We did not examine students at that time. Contacts were persons from the same household or neighborhood whom the index case-patient described as a person with whom he or she had a close relationship. Leprosy cases were diagnosed in the field on the basis of clinical signs, loss of sensation on the skin lesions, and presence of enlarged nerves. For operational reasons, skin smears were not performed. All cases were diagnosed by 2 leprologists. We used the Ridley-Jopling classification, associated with the indeterminate clinical type, as defined by the Madrid classification. The ELISA cutoff for positive results was arbitrarily established as an optical density of 0.295 based on the average plus 3× the SD of the test results from 14 healthy persons from the Amazon region (5).
Because studies of the seroprevalence among contacts have reported a proportion of seropositive persons ranging from ≈1.9% to 18.4% (6), we returned to Oriximiná 16 months after the first visit. We examined 2 groups of students and their contacts; 1 group was positive for anti–PGL-I, and the other group was negative for anti–PGL-I. We visited 44 households in 1 week. From the 35 leprosy patients encountered during the first visit, we selected 25 households to survey (14 with an anti–PGL-I–positive contact in the household and 11 without), and among students with results of anti–PGL-I serology, we selected 19 households (11 positive with an anti–PGL-I–positive contact in the household and 8 without). During our visits to all of these households, we examined 222 persons (Table).
When we arrived in Oriximiná, only 2 cases had been registered in the national notifiable diseases information system. By using our approach, 23 new cases were found after we investigated households that had a person positive for anti–PGL-I (15 multibacillary, 8 paucibacillary); we found only 7 new cases in households where residents were negative for anti–PGL-I (4 multibacillary, 3 paucibacillary) (Table). For comparison, during the last traditional leprosy campaign in Oriximiná in 2008, eight new cases were detected. Furthermore, by using our strategy, the local public health service detected 9 additional new cases during the 4 months after our departure from Oriximiná.
These data emphasize that contact examination is crucial for identifying new cases (7) and that such investigation must be conducted periodically. Our data also indicate that subclinical infections are highly prevalent among public school students in the Amazon region and that identifying students with positive anti–PGL-I test results can lead to discovery of new leprosy cases among students’ household contacts.
We thank André Luiz Correa de Sousa, Márcia Leão, and Anna Elizabeth Martins Alves for collecting the samples and data from the patients; Sabrina Sampaio Bandeira for the patient impairment evaluation; Domingos Diniz, Miguel Canto, and the Programa de Ação Interdiciplinar at Oriximiná for logistical support and fruitful discussions; John Spencer for supplying the native PGL-I and technical support with the ELISA; the Oriximiná health secretary and community health agents; and the study participants.
C.G.S. designed and coordinated the study; clinically examined, diagnosed, and classified the subjects; statistically analyzed the data; and wrote the manuscript. D.V.G.F. collected and processed the samples, performed laboratory assays, and statistically analyzed the data. M.A.C.F. clinically examined, diagnosed leprosy, and classified the subjects. L.S.G. evaluated the functional statuses of the subjects. M.B.S. performed laboratory assays. J.G.B. designed the study and interviewed the participants. All authors participated in the interpretation of the data and read and approved the final manuscript.
This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ: neglected diseases grant 576425/2008-7 and scholarship for C.G.S.), by the Secretaria Executiva de Saúde Pública do Estado do Pará and by the Universidade Federal do Pará.
- Burki T. Old problems still mar fight against ancient disease. Lancet. 2009;373:287–8.
- Moet FJ, Schuring RP, Pahan D, Oskam L, Richardus JH. The prevalence of previously undiagnosed leprosy in the general population of northwest Bangladesh. PLoS Negl Trop Dis. 2008;2:e198.
- Penna G, Pinto L, Soranz D, Glatt R. High incidence of diseases endemic to the Amazon region of Brazil, 2001–2006. Emerg Infect Dis. 2009;15:626–32.
- World Health Organization. Leprosy update, 2011. Wkly Epidemiol Rec. 2011;86:389–99.
- Barreto JG, Guimarães LS, Leão MRN, Ferreira DVG, Lima RAA, Salgado CG. Anti-PGL-I seroepidemiology in leprosy cases: household contacts and school children from a hyperendemic municipality of the Brazilian Amazon. Lepr Rev. 2011;82:358–70.
- Moura RS, Calado KL, Oliveira ML, Büher-Sékula S. Leprosy serology using PGL-I: a systematic review. Rev Soc Bras Med Trop. 2008;41(Suppl 2):11–8.
- World Health Organization. Enhanced global strategy for further reducing the disease burden due to leprosy (plan period: 2011-2015). New Delhi (India): WHO Regional Office for South-East Asia; 2009.
- Table. New leprosy cases detected among selected households, Oriximiná, Pará State, Brazilian Amazon, 2010
Please use the form below to submit correspondence to the authors or contact them at the following address:
Claudio Guedes Salgado, Laboratório de Dermato-Imunologia UEPA/UFPA/MC, Av João Paulo II, 113, Bairro Dom Aristides, CEP: 67200-000, Marituba, Pará, Brazil
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: April 06, 2012
- Page last updated: April 06, 2012
- Page last reviewed: April 06, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)